Can AI help Biomunex find better bispecific antibody targets in cancer?
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?
Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.
Pierre Fabre and Iktos partner on AI-designed small-molecule cancer therapies
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.
From ARPA-H to Basilea: What Phare Bio’s new deal reveals about biotech partnerships
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.